Abstract
Breast cancer is the most commonly diagnosed cancer in American women and is the second leading cause of cancer-related deaths in this population. This review highlights how the use of a multidisciplinary approach to the management of diseases of the breast and the introduction of novel systemic therapies have improved the quality of life and survival in patients with breast cancer.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Bone Neoplasms / drug therapy
-
Bone Neoplasms / secondary
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Breast Neoplasms / therapy*
-
Chemotherapy, Adjuvant
-
Diphosphonates / therapeutic use
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / metabolism
-
Female
-
Humans
-
Neoadjuvant Therapy
-
Patient Care Team
-
Patient Selection
-
Protein Kinase Inhibitors / therapeutic use
-
Quality of Life
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
-
Receptors, Vascular Endothelial Growth Factor / metabolism
-
Therapies, Investigational
-
Treatment Outcome
-
United States
Substances
-
Antineoplastic Agents
-
Antineoplastic Agents, Hormonal
-
Diphosphonates
-
Protein Kinase Inhibitors
-
ErbB Receptors
-
Receptors, Vascular Endothelial Growth Factor